1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

US orphan status for Angioblast's stem cell therapy

 
• By Ian Haydock

The US FDAhas granted orphan status to Angioblast Systems' allogeneic mesenchymal precursor cell therapy for use in cancer patients receiving bone marrow transplants. The non-patient-specific cells will be used to regenerate damaged bone marrow and help transplants engraft in cases of insufficient haematopoietic stem cell production in patients with haematologic malignancies who have failed conventional chemotherapy. Angioblast is 39% owned by the Australian firm Mesoblast, which is developing various stem cell-based therapies (Scrip Online, August 18th, 2008).

The US FDAhas granted orphan status to Angioblast Systems' allogeneic mesenchymal precursor cell therapy for use in cancer patients receiving bone marrow transplants. The non-patient-specific cells will be used to regenerate damaged bone marrow and help transplants engraft in cases of insufficient haematopoietic stem cell production in patients with haematologic malignancies who have failed conventional chemotherapy. Angioblast is 39% owned by the Australian firm Mesoblast, which is developing various stem cell-based therapies (Scrip Online, August 18th, 2008).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

More from Therapeutic Category

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.